Intravenous (IV) Vitamin C
IVC therapy is the intravenous infusion of high dose vitamin C. Recent advances have shown a very large increase in the use of intravenous vitamin C among several leading oncology units across North America.
At blood levels of 2000 umol/L, only achievable through intravenous administration, vitamin C is selectively cytotoxic to cancer cells. The ability of IVC to prolong survival, improve quality of life, and reduce adverse effects of conventional therapies has been reproducibly demonstrated over several decades.
Physiologic concentrations of vitamin C are tightly controlled through oral ingestion. Intravenous administrations can by-pass the tight control mechanism and force cancer cells to uptake vitamin C. Intravenous vitamin C sensitizes cancer cells to most chemotherapy drugs while modulating the immune system to prevent neutropenia. In contrast to its normal anti-oxidant role, vitamin C in pharmacologic concentrations has pro-oxidant action by generating hydrogen peroxide within cancer cells. This pro-oxidant action of vitamin C induces selective cell death to some cancer cells but not to normal cells.
Since IVC generated pro-oxidants instead of anti-oxidants it is complimentary to oncologic care. Intravenous vitamin C can be used in conjunction with chemotherapy. Cancer patients consistently report that IVC helps them tolerate the effects of their traditional therapies. Further benefits to IVC include significantly reduced fatigue, nausea, pain and improved appetite. Patients heal faster, are more resilient to infection and remain more active overall. All of these factors promote healing and an improved response to cancer therapy.
What is the recommended protocol for Intravenous vitamin C?
Intravenous vitamin C takes 1-2 hrs to administer. Treatments are typically 2-3 times per week during active treatment and less often during maintenance phase. The goal of IVC treatment is to achieve a concentration in the blood of 400md/dL which is typically between 40g to 75 g of vitamin C. All of our patients are pre-screened for G6PD deficiency prior to treatment initiation.
Intravenously administered vitamin C as cancer therapy: three cases
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.